SOURCES:

Colleen Krejewski, MD, assistant professor of Obstetrics, Gynecology, and Reproductive Sciences, College of Pittsburgh.

Sheila Chhutani, MD, OB-GYN, Texas Well being Presbyterian Hospital Dallas.

Richard Kaye, MD, OB-GYN, Texas Well being Presbyterian Hospital Plano.

American Congress of Obstetricians and Gynecologists, Committee Opinion: “Threat of Venous Thromboembolism Amongst Customers of Drospirenone-Containing Oral Contraceptive Drugs.”

Facilities for Illness Management: Abstract Chart of U.S. Medical Eligibility Standards for Contraceptive Use.

FamilyDoctor.org: Progestin-Solely Contraceptives.

Nationwide Most cancers Institute: Oral Contraception and Most cancers Threat.

Marchbanks, PA, Contraception, April 2012.

Bedsider.org: “What’s the Threat?”

FDA.gov: Depo-Provera Contraceptive injection (medroxyprogesterone acetate) injectable suspension

Berenson, A, American Journal of Obstetrics & Gynecology, March, 2009

American Congress of Obstetricians and Gynecologists, Committee Opinion: “Depot Medroxyprogesterone Acetate and Bone Results”

Deliberate Parenthood: “IUD,” “When does an IUD begin working?”

Affiliation of Reproductive Well being Professionals: “Well being Issues Truth Sheets: Copper T IUD,” “Non-hormonal Contraceptive Strategies,” “Strategies Match.”